Awwad Shady T, El-Kateb Mohamed, Bowman R Wayne, Cavanagh H Dwight, McCulley James P
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9057, USA.
J Refract Surg. 2004 Sep-Oct;20(5):S606-13. doi: 10.3928/1081-597X-20040901-38.
To evaluate and compare the visual and clinical outcomes of wavefront-guided laser in situ keratomileusis (LASIK) with the Alcon CustomCornea (Alcon Laboratories Inc, Fort Worth, Tex) and VISX CustomVue (VISX, Santa Clara, Calif) systems.
Ninety-three eyes of 56 patients (50 and 43 consecutive eyes on CustomCornea and CustomVue, respectively) were enrolled in a prospective multisurgeon clinical outcome study. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and manifest refraction were measured at 1 day, 1 week, 1 month, and 3 months postoperatively. Early treatment diabetic retinopathy study (ETDRS) visual acuity and contrast sensitivity were measured at 1 month and 3 months, and wavefront mapping at 3 months.
Preoperatively, the CustomCornea group had a mean sphere of -3.90 +/- 1.62 diopters (D) (range -0.50 to -7.25 D), mean cylinder of +0.62 +/- 0.39 D (range 0 to +1.50 D), and mean manifest spherical equivalent refraction of -3.59 +/- 1.54 D. The CustomVue group had a sphere of -3.87 +/- 1.45 D (range -1.75 to -6.75 D), cylinder of +0.49 +/- 0.36 D (range 0 to +1.50 D), and manifest spherical equivalent refraction of -3.62 +/- 1.46 D. At 3 months, 98% of the CustomCornea group and 95% of the CustomVue group were within +/-0.50 D. Ninety-nine percent of eyes did not change >0.50 D (manifest spherical equivalent refraction) between 1 month and 3 months. CustomCornea eyes improved on contrast sensitivity testing and had a better profile than CustomVue for 20/15 Snellen and 20/12.5 ETDRS acuity. Both laser groups had a decrease in higher order aberrations with statistical significance for coma and spherical aberration in the CustomCornea group.
Wavefront-guided LASIK with both systems is safe and effective.
评估并比较使用爱尔康CustomCornea（爱尔康实验室公司，沃思堡，得克萨斯州）和威视VISX CustomVue（威视公司，圣克拉拉，加利福尼亚州）系统的波前引导准分子原位角膜磨镶术（LASIK）的视觉和临床效果。
56例患者的93只眼（分别有50只和43只连续眼接受CustomCornea和CustomVue治疗）纳入一项前瞻性多医生临床效果研究。术后1天、1周、1个月和3个月测量裸眼视力（UCVA）、最佳矫正视力（BSCVA）和显验光。在1个月和3个月时测量早期糖尿病性视网膜病变研究（ETDRS）视力和对比敏感度，在3个月时进行波前像差测量。
术前，CustomCornea组平均球镜度数为-3.90±1.62屈光度（D）（范围为-0.50至-7.25 D），平均柱镜度数为+0.62±0.39 D（范围为0至+1.50 D），平均显验光球镜等效度数为-3.59±1.54 D。CustomVue组球镜度数为-3.87±1.45 D（范围为-1.75至-6.75 D），柱镜度数为+0.49±0.36 D（范围为0至+1.50 D），显验光球镜等效度数为-3.62±1.46 D。3个月时，CustomCornea组98%的患者和CustomVue组95%的患者屈光度在±0.50 D以内。99%的眼睛在1个月至3个月间显验光球镜等效度数变化不超过0.50 D。CustomCornea组患者在对比敏感度测试中有所改善，对于20/15 Snellen视力和20/12.5 ETDRS视力，其表现优于CustomVue组。两组激光治疗均使高阶像差减少，CustomCornea组在彗差和球差方面具有统计学意义。
两种系统的波前引导LASIK均安全有效。
